Boothbay Fund Management LLC Decreases Position in Novo Nordisk A/S (NYSE:NVO)

Boothbay Fund Management LLC lowered its stake in Novo Nordisk A/S (NYSE:NVO - Free Report) by 65.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 22,833 shares of the company's stock after selling 43,439 shares during the quarter. Boothbay Fund Management LLC's holdings in Novo Nordisk A/S were worth $1,964,000 at the end of the most recent reporting period.

Several other large investors also recently made changes to their positions in the stock. Passumpsic Savings Bank grew its holdings in shares of Novo Nordisk A/S by 0.9% during the third quarter. Passumpsic Savings Bank now owns 21,448 shares of the company's stock worth $2,554,000 after buying an additional 194 shares in the last quarter. Virtu Financial LLC boosted its holdings in Novo Nordisk A/S by 69.8% during the third quarter. Virtu Financial LLC now owns 33,929 shares of the company's stock worth $4,040,000 after purchasing an additional 13,949 shares during the last quarter. Tudor Financial Inc. acquired a new stake in Novo Nordisk A/S in the 3rd quarter valued at $311,000. Anchor Investment Management LLC boosted its stake in shares of Novo Nordisk A/S by 2.3% during the 3rd quarter. Anchor Investment Management LLC now owns 13,447 shares of the company's stock worth $1,601,000 after buying an additional 297 shares during the last quarter. Finally, World Investment Advisors LLC increased its position in shares of Novo Nordisk A/S by 36.9% in the third quarter. World Investment Advisors LLC now owns 13,925 shares of the company's stock valued at $1,655,000 after acquiring an additional 3,750 shares during the last quarter. Institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Stock Down 1.3 %

Shares of NYSE:NVO traded down $0.89 during mid-day trading on Thursday, hitting $65.57. 11,646,729 shares of the company traded hands, compared to its average volume of 6,174,446. The company has a current ratio of 0.74, a quick ratio of 0.55 and a debt-to-equity ratio of 0.62. The stock has a market cap of $294.23 billion, a P/E ratio of 19.92, a P/E/G ratio of 0.90 and a beta of 0.61. The stock has a 50-day moving average price of $72.40 and a two-hundred day moving average price of $88.69. Novo Nordisk A/S has a 12-month low of $57.00 and a 12-month high of $148.15.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last announced its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a return on equity of 84.68% and a net margin of 34.81%. On average, equities research analysts forecast that Novo Nordisk A/S will post 3.84 earnings per share for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently declared a semi-annual dividend, which was paid on Tuesday, April 8th. Stockholders of record on Monday, March 31st were issued a $0.7874 dividend. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. The ex-dividend date of this dividend was Monday, March 31st. This represents a dividend yield of 1.2%. Novo Nordisk A/S's dividend payout ratio is presently 49.54%.

Analyst Ratings Changes

A number of brokerages have recently issued reports on NVO. Morgan Stanley assumed coverage on Novo Nordisk A/S in a research note on Wednesday, February 12th. They set an "equal weight" rating on the stock. Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Kepler Capital Markets raised shares of Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. StockNews.com upgraded shares of Novo Nordisk A/S from a "buy" rating to a "strong-buy" rating in a research note on Friday, April 25th. Finally, Sanford C. Bernstein raised Novo Nordisk A/S from an "underperform" rating to a "market perform" rating in a research report on Monday, January 6th. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, Novo Nordisk A/S currently has a consensus rating of "Moderate Buy" and a consensus price target of $135.00.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.